<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02238860</url>
  </required_header>
  <id_info>
    <org_study_id>AIMS-hep B-123</org_study_id>
    <nct_id>NCT02238860</nct_id>
  </id_info>
  <brief_title>A Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis</brief_title>
  <official_title>A Randomised Trial Comparing Entacavir and Tenofovir in Patients With HBV Decompensated Cirrhosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Asian Institute Of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Asian Institute Of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Entacavir and tenofovir are two first line therapies for chronic hepatitis B. Both agents
      have been claimed equivalent in treatment, there are no head to head trials available in the
      literature about there effectiveness in HBV Decompensated Cirrhosis. The investigators aimed
      to compare safety/efficacy and virological response in patients with HBV Decompensated
      Cirrhosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The effectiveness of entacavir and tenofovir has not been prospectively studied in HBV
      Decompensated cirrhosis? This prospective, randomised clinical trial will help us in better
      patient management more efficacy and cost effectiveness.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2014</start_date>
  <completion_date type="Anticipated">September 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and efficacy</measure>
    <time_frame>48 weeks</time_frame>
    <description>EFFICACY ENDPOINTS: EFFICACY ENDPOINTS INCLUDED PLASMA HBV DNA, ALT, HBEAG, HBSAG LOSS AND SEROCONVERION AS WELL AS CTP AND MELD SCORE.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>48 weeks</time_frame>
    <description>SAFETY ENDPOINTS: SAFETY ANALYSIS INCLUDED CUMALATIVE RATES ON TREATMENT ADVERSE EVENTS, SEREIOUS ADVERSE EFFECTS DISCONTINUATION DUE TO SIDE EFFECTS,DEATH,HCC,RENAL IMPAIRMENT , HEPATIC FLARE AND DEVELOPMENT OF DRUG RESISTANCE.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Outcome</measure>
    <time_frame>48 weeks</time_frame>
    <description>Death</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Cirrhosis Due to Hepatitis B</condition>
  <arm_group>
    <arm_group_label>Entacavir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Entacavir 0.5 mg (OD) for 48 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tenofovir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Tenofovir 300 mg ,OD for 48 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Entacavir</intervention_name>
    <description>Entacavir-0.5 mg ,OD,for</description>
    <arm_group_label>Entacavir</arm_group_label>
    <arm_group_label>Tenofovir</arm_group_label>
    <other_name>ETV</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tenofovir</intervention_name>
    <description>Tenofovir ,300 mg,OD,for 48 weeks</description>
    <arm_group_label>Entacavir</arm_group_label>
    <arm_group_label>Tenofovir</arm_group_label>
    <other_name>TDF or PMPA</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age (18 years- 70 years)

          -  Hbv surface antigen positive &gt; 6 months

          -  HbeAg (positive or negative both)

          -  Hbv DNA 10^3

          -  ALT ULN

          -  No evidence of HCC

          -  Platelets count &gt; 30 thousands

          -  CTP score &gt; 7

          -  Hepatic encephalopathy (grade 1 - 2 only)

          -  No prior Drug resistance

        Exclusion Criteria:

          -  Age &lt; 18 years

          -  HCC patients

          -  Prior drug resistance

          -  Current HE &gt; 2

          -  Solid organ transplantation

          -  Inadequate hematological function

          -  Co infection with hepatitis C and HIV

          -  Autoimmune disorders

          -  Pregnancy and Breast feeding

          -  Other hepatic diseases

          -  Patients on immunosuppressant or chemotherapy agents
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohammad sadik Memon, Fcps gastro</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aims</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Dr mohammad sadik Memon, Fcps gastro</last_name>
    <phone>022-232593</phone>
    <email>Sadikmemon@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Madiha Zaki, MSC gastro</last_name>
    <phone>022-232593</phone>
    <email>Madiyaah@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Asian Institute of medical Sciences</name>
      <address>
        <city>Hyderabad</city>
        <state>Sindh</state>
        <zip>71800</zip>
        <country>Pakistan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr mohammad sadik Memon, FCPS gastro</last_name>
      <phone>022-232593</phone>
      <email>Sadikmemon@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Dr sadik Memon, FCPS gastro</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Madiha Zaki, MSC gastro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr NANDLAL Serani, FCPS gastro</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dr Umar Soomro, MBBS</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Pakistan</country>
  </location_countries>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 10, 2014</study_first_submitted>
  <study_first_submitted_qc>September 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2014</study_first_posted>
  <last_update_submitted>September 11, 2014</last_update_submitted>
  <last_update_submitted_qc>September 11, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Asian Institute Of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Mohammad sadik memon</investigator_full_name>
    <investigator_title>Professor of gastroenterology</investigator_title>
  </responsible_party>
  <keyword>Hepatitis B</keyword>
  <keyword>cirrhosis</keyword>
  <keyword>Entacavir</keyword>
  <keyword>enofovir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis B</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tenofovir</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

